Status message

Not the entire site translated, but only to "Journal"

Когнитивные нарушения при аффективных расстройствах. Способы диагностики и возможности коррекции

Yanushko M.G.1, Shamanina M.V.1,Keefe R.S.E.2, Shipilin M.J.2
1Federal Budgetary Institution Bekhterev Psychoneurological Research Institute of Ministry of Health of the Russian Federation, St. Petersburg
2Duke University Medical Center, Durham, USA

SUMMARY. Patients with bipolar or unipolar depression often experience cognitive deficit persisting both in the acute state and during remission. The review examines opportunities of psychopharmacological influence upon cognitive disorders evidence in this cohort of patients. Approaches towards cognitive functioning diagnostics in affective disorders with taking into consideration the evidence based approach to the peculiarities of affective spectrum patients is also overviewed.

References: 
  • 1. Marazziti D., Consoli G., Picchetti M. et al. Cognitive impairment in major depression // Eur J Pharmacol. – 2010. – Vol. 626 (1). – R. 83–86.
  • 2. Gorlyn M., Keilp J., Burke A. et al. Neurocognitive impairment in MDD is an independent component of symptom severity // Biol Psychiatry. – 2012. – Vol. 71 (suppl. 1). – P. 864– 876.
  • 3. Reppermund S., Ising M., Lucae S. et al. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis // Psychol Med. – 2009. – Vol. 39 (4). – R. 603–614.
  • 4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. – Washington, DC: American Psychiatric Association, 2013.
  • 5. Maalouf F.T., Brent D., Clark L. et al. Neurocognitive impairment in adolescent major depressive disorder: state vs trait illness markers // Affect Disord. – 2011. – Vol. 133. – P. 625–632.
  • 6. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment // J Clin Psychiatry. – 2003. – Vol. 64 (suppl. 14). – R. 30–34.
  • 7. Trivedi M.H., Rush A.J., Wisniewski S.R. et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice // Am J Psychiatry. – 2006. – Vol. 163 (1). – R. 28–40.
  • 8. McClintock S.M., Husain M.M., Wisniewski S.R. et al. Residual symptoms in depressed outpatients who respond by 50 % but do not remit to antidepressant medication // J Clin Psychopharmacol. – 2011. – Vol. 31 (2). – R.180–186.
  • 9. Gorodnichev A.V., Kostyukova E.G., Mosolov S.N. Dostizhenie remissii kak osnovnaya cel' dlitel'noj terapii rekurrentnogo depressivnogo rasstrojstva (analiz dannyh literatury i rezul'tatov original'nogo sravnitel'nogo randomizirovannogo issledovaniya antidepressantov raznyh pokolenij) // Sovremennaya terapiya psihicheskih rasstrojstv. – 2009. – T. 1. – S. 5–10.
  • 10. Kostyukova E.G. Aripiprazol kak sredstvo augmentacii pri neeffektivnosti terapii antidepressantami u bol'nyh s bol'shim depressivnym rasstrojstvom // Social'naya i klinicheskaya psihiatriya. – T. 20, vyp. 3. – S. 100–105.
  • 11. Mosolov S.N., Kostyukova E.G., Kuzavkova M.V. Profilakticheskoe primenenie antikonvul'santov pri faznoprotekayushchih endogennyh psihozah (sravnitel'noe izuchenie karbamazepina, val'proata natriya i solej litiya) // Antikonvul'santy v psihiatricheskoj i nevrologicheskoj praktike / pod red. A.M. Vejna, S.N. Mosolova. – SPb.: Medicinskoe informacionnoe agentstvo, 1994. – S. 72–128.
  • 12. Mazo G.E. Normotimiki v lechenii terapevticheski rezistentnyh depressij: protivorezistentnaya terapiya ili vliyanie na skrytuyu bipolyarnost'? // Obozrenie psihiatrii i medicinskoj psihologii im. V.M. Bekhtereva. – 2014. – № 3. – S. 91–96.
  • 13. Keefe R.S., McClintock S.M., Roth R.M., Doraiswamy P.M., Tiger S., Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review // J Clin Psychiatry. – 2014. – Vol. 75 (8). – R. 864–876.
  • 14. Austin M.P., Mitchell P., Hadzi-Pavlovic D. et al. Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report // Psychiatry Res. – 2000. – Vol. 97 (2–3). – R. 207–215.
  • 15. Kok R.M., Vink D., Heeren T.J. et al. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial // J Clin Psychiatry. –2007. –Vol. 68 (8). – R. 1177–1185.
  • 16. Morgan M.L., Cook I.A., Rapkin A.J. et al. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study // J Clin Psychiatry. – 2005 – Vol. 66 (6). – P. 774–780.
  • 17. Greer T.L., Sunderajan P., Grannemann B.D. et al. Aripiprazole augmentation improves aspects of executive function in major depressive disorder: a pilot study // Neuropsychopharmacology. – 2011. – Vol. 36 (suppl. 1). – P. 350–351.
  • 18. Politis A.M., Papadimitriou G.N., Theleritis C.G. et al. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression // Prog Neuropsychopharmacol Biol Psychiatry. – 2008. – Vol. 32 (5)yu – P. 1227–1230.
  • 19. Hinkelmann K., Moritz S., Botzenhardt J. et al. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study // Psychoneuroendocrinology. – 2012 – Vol. 37 (5). – P. 685–692.
  • 20. Elgamal S., MacQueen G. Galantamine as an adjunctive treatment in major depression // J. Clin. Psychopharmacol. – 2008 – Vol. 28 (3). – P. 357–359.
  • 21. Reynolds C.F. 3rd, Butters M.A., Lopez O. et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy // Arch Gen Psychiatry. – 2011. – Vol. 68 (1). – P. 51–60.
  • 22. Murrough J.W., Wan L.B., Glicksberg B. et al. Ketamine and neurocognition in depression: the modulating effects of lamotrigine // Neuropsychopharmacology. – 2012. – Vol. 38. – P. 375.
  • 23. Madhoo M., Keefe R.S.E., Roth R.M. et al. Efficacy and safety of lidexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder // Int J Neuropsychopharmacol. – 2012. – Vol. 15 (suppl.). – P. 189.
  • 24. Wroolie T.E., Williams K.E., Keller J. et al. Mood and neuropsychological changes in women with midlife depression treated with escitalopram // J Clin Psychopharmacol. – 2006. – Vol. 26 (4). – P. 361–366.
  • 25. Herrera-Guzmán I., Herrera-Abarca J.E., Gudayol-Ferré E. et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder // Psychiatry Res. –2010. – Vol. 177 (3). – P. 323–329.
  • 26. DeBattista C., Lembke A., Solvason H.B. et al. A prospective trial of modafinil as an adjunctive treatment of major depression // J Clin Psychopharmacol. – 2004 – Vol. 24 (1). – P. 87–90.
  • 27. Culang-Reinlieb M.E., Sneed J.R., Keilp J.G. et al. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline // Int J Geriatr Psychiatry. – 2009. – Vol. 17 (10). – P. 881–888.
  • 28. Deuschle M., Kniest A., Niemann H. et al. Impaired declarative memory in depressed patients is slow to recover: clinical experience // Pharmacopsychiatry. – 2004 – Vol. 37 (4). – P. 147–151.
  • 29. Doraiswamy P.M., Krishnan K.R., Oxman T. et al. Does antidepressant therapy improve cognition in elderly depressed patients? // J Gerontol A Biol Sci Med Sci. – 2003. – Vol. 58 (12). – P. 1137–1144.
  • 30. Devanand D.P., Pelton G.H., Marston K. et al. Sertraline treatment of elderly patients with depression and cognitive impairment // Int J Geriatr Psychiatry. 2003. – Vol. 18 (2). – P. 123–130
  • 31. Nickel T., Sonntag A., Schill J. et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression // J Clin Psychopharmacol. – 2003. – Vol. 23 (2). – P. 155–168.
  • 32. Boeker H., Schulze J., Richter A. et al. Sustained cognitive impairments after clinical recovery of severe depression // J Nerv Ment Dis. – 2012. – Vol. 200 (9). – P. 773–776.
  • 33. Ferguson J.M., Wesnes K.A., Schwartz G.E. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients // Int Clin Psychopharmacol. – 2003. – Vol. 18 (1). – P. 9–14.
  • 34. Holtzheimer P.E. 3rd, Meeks T.W., Kelley M.E. et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression // Int J Geriatr Psychiatry. – 2008. –Vol. 23 (6). – P. 625–631.
  • 35. Pelton G.H., Harper O.L., Tabert M.H. et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study // Int J Geriatr Psychiatry. – 2008. – Vol. 23 (7). – P. 670–676.
  • 36. Levkovitz Y., Alpert J.E., Brintz C.E. et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder // J Affect Disord. – 2012. – Vol. 136 (3). – P. 1174–1178.
  • 37. Raskin J., Wiltse C.G., Siegal A. et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial // Am J Psychiatry. – 2007. – Vol. 164 (6). – P. 900–909.
  • 38. Wise T.N., Wiltse C.G., Iosifescu D.V. et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity // Int J Clin Pract. – 2007. – Vol. 61 (8). – P. 1283–1293.
  • 39. Reilly J.L., Lencer R., Thase M.E. et al. Effects of sertraline on neurocognition in outpatients with major depressive disorder // Neuropsychopharmacology. – 2011. – Vol. 36 (suppl. 1). – P. 117–118.
  • 40. Sato S., Yamakawa Y., Terashima Y. et al. Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study // Psychiatry Clin Neurosci. – 2006. – Vol. 60 (5). – P. 584–589.
  • 41. Spalletta G., Caltagirone C. Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms // Funct Neurol. – 2003. – Vol. 18 (4). – P. 227–232.
  • 42. Bondareff W., Alpert M., Friedhoff A.J. et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life // Am J Psychiatry. – 2000. – Vol. 157 (5). – P. 729–736.
  • 43. Finkel S.I., Richter E.M., Clary C.M. et al. Comparative efficacy of sertraline vs fluoxetine in patients age 70 or over with major depression // Am J Geriatr Psychiatry. – 1999. – Vol. 7 (3). – P. 221–227.
  • 44. Newhouse P.A., Krishnan K.R., Doraiswamy P.M. et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients // J Clin Psychiatry. – 2000. – Vol. 61 (8). – P. 559–568.
  • 45. Chang H.H., Lee I.H., Gean P.W. et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein // Brain Behav Immun. – 2012. – Vol. 26 (1). – P. 90–95.
  • 46. Green M.F., Nuechterlein K.H., Gold J.M. et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria // Biol Psychiatry. – 2004. – Vol. 56 (5). –P. 301–307.
  • 47. Yatham L.N, Torres I.J., Malhi G.S., Frangou S., Glahn D.C. et al. The International Society for Bipolar Disorders–Battery for Assessment of Neurocognition (ISBD-BANC) // Bipolar Disorders. – 2010. – Vol. 12, iss. 4. – P. 351–363.
  • 48. Elliott R., Zahn R., Deakin J.F., Anderson I.M. Affective cognition and its disruption in mood disorders // Neuropsychopharmacology. – 2011. – Vol. 36. – P. 153–182.
  • 49. Keefe R.S., Harvey P.D., Goldberg T.E. et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) // Schizophr. Res. – 2008. – Vol. 102, no 1–3. – P. 108–115.
  • 50. Keefe R.S.E., Fox K.H., Davis V.G., Kennel C., Walker T.M., Burdick K., Harvey P.D. The Brief Assessment of Cognition In Affective Disorders (BAC-A): Performance of patients with bipolar depression and healthy controls // Journal of Affective Disorders. – 2014. – Vol. 166. – P. 86–92.
  • 51. Yanushko M.G., Shamanina M.V., Aristova T.A., Kif R.S., Ivanov M.V., Tolmacheva M. Standartizaciya shkaly «Kratkaya ocenka kognitivnyh funkcij u pacientov s affektivnymi rasstrojstvami» (BAC-A) na osnove normativnyh dannyh rossijskoj populyacii // Rossijskij psihiatricheskij zhurnal. – 2015. – № 2. – S.68–75.